Serum Cholinesterase Levels Are Associated With 2-Year Ischemic Outcomes After Angioplasty and Stenting for Peripheral Artery Disease
- 10 July 2016
- journal article
- research article
- Published by SAGE Publications in Journal of Endovascular Therapy
- Vol. 23 (5) , 738-743
Abstract
Purpose: To prospectively investigate the associations of serum cholinesterase (CHE) levels with ischemic outcomes after angioplasty and stenting for lower limb peripheral artery disease (PAD). Methods: A prospective cohort study enrolled 108 patients with Rutherford category 2–3 ischemia who had successful primary unilateral angioplasty and self-expanding bare metal stent implantation for superficial femoral artery (SFA) stenosis. The primary endpoint was a composite of nonfatal myocardial infarction, nonfatal stroke or transient ischemic attack, cardiovascular death, or >80% target lesion restenosis within 2 years after peripheral angioplasty. Target lesion restenosis (restenosis endpoint) and the composite of the aforementioned atherothrombotic events (atherothrombotic endpoint) within 2-year follow-up were defined as secondary endpoints. Results: CHE levels were not available in 4 patients due to technical problems and 4 patients were lost to follow-up. The remaining 100 patients (median age 65 years; 62 men) met the minimum sample size requirement for statistical analysis. Median CHE levels were significantly lower in patients who subsequently experienced the primary endpoint compared with patients without ischemic events [7.1 (IQR 6.3–8.1) vs 8 (IQR 7–9.3) kU/L, p=0.007]. A CHE level <8.3 kU/L was identified as the best cutoff value to predict the primary endpoint, providing an 82.1% sensitivity and 44.3% specificity. The primary endpoint occurred significantly more often in patients with low CHE <8.3 kU/L than in patients with higher CHE levels (32 vs 7 patients, p=0.01). In multivariable Cox regression analysis, low CHE was associated with a 2.6-fold increased risk (95% CI 1.1 to 5.9, p=0.03) of the primary endpoint. Moreover, patients who suffered the secondary restenosis endpoint had significantly lower median CHE levels than patients without restenosis [7.1 (IQR 6.3–8.2) vs 7.9 (IQR 7–8.9) kU/L, p=0.02], and restenosis occurred more frequently in patients with low CHE compared with those with higher CHE levels (27 vs 7 patients, p=0.04). Conclusion: Low CHE is associated with an increased risk of long-term adverse ischemic events following SFA angioplasty with stent implantation for PAD.Keywords
This publication has 14 references indexed in Scilit:
- Decline in Serum Cholinesterase Activities Predicts 2-Year Major Adverse Cardiac EventsMolecular Medicine, 2013
- Long-term prognosis of patients with peripheral arterial disease with or without polyvascular atherosclerotic diseaseEuropean Heart Journal, 2009
- Chronotropic incompetence and mortality in middle-aged men with known or suspected coronary heart diseaseEuropean Heart Journal, 2008
- Relation of Heart Rate Parameters During Exercise Test to Sudden Death and All-Cause Mortality in Asymptomatic MenThe American Journal of Cardiology, 2008
- Long-Term Prognosis of Patients With Peripheral Arterial DiseaseJACC, 2008
- Prognostic Value of Heart Rate Increase at Onset of Exercise TestingCirculation, 2007
- Prognostic value of heart rate recovery in patients with heart failureAmerican Heart Journal, 2006
- Heart-Rate Profile during Exercise as a Predictor of Sudden DeathNew England Journal of Medicine, 2005
- Acetylcholinesterase — new roles for an old actorNature Reviews Neuroscience, 2001
- Heart-Rate Recovery Immediately after Exercise as a Predictor of MortalityNew England Journal of Medicine, 1999